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Cystic Fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator 
(CFTR). Newly developed “correctors” such as lumacaftor (VX-809) that improve CFTR 
maturation and trafficking and “potentiators” such as ivacaftor (VX-770) that enhance channel 
activity may provide important advances in CF therapy. Although VX-770 has demonstrated 
substantial clinical efficacy in the small subset of patients with a mutation (G551D) that affects 
only channel activity, a single compound is not sufficient to treat patients with the more common 
CFTR mutation, ΔF508. Thus, patients with ΔF508 will likely require treatment with both 
correctors and potentiators to achieve clinical benefit. However, whereas the effectiveness of acute 
treatment with this drug combination has been demonstrated in vitro, the impact of chronic 
therapy has not been established. In studies of human primary airway epithelial cells, we found 
that both acute and chronic treatment with VX-770 improved CFTR function in cells with the 
G551D mutation, consistent with clinical studies. In contrast, chronic VX-770 administration 
caused a dose-dependent reversal of VX-809-mediated CFTR correction in ΔF508 homozygous 
cultures. This result reflected the destabilization of corrected ΔF508 CFTR by VX-770, 
dramatically increasing its turnover rate. Chronic VX-770 treatment also reduced mature wild-
type CFTR levels and function. These findings demonstrate that chronic treatment with CFTR 
potentiators and correctors may have unexpected effects that cannot be predicted from short-term 
studies. Combining of these drugs to maximize rescue of ΔF508 CFTR may require changes in 
dosing and/or development of new potentiator compounds that do not interfere with CFTR 
stability.
Introduction
The most common autosomal recessive genetic disease of the Caucasian population in the 
United States and Europe, cystic fibrosis (CF), is characterized by abnormal epithelial ion 
transport. Mutations in the CF transmembrane conductance regulator (CFTR) result in loss 
of CFTR-mediated Cl− and HCO3− transport by secretory and absorptive epithelial cells in 
multiple organs, including lungs, pancreas, liver, and intestine. In the lung, disturbances of 
airway surface liquid homeostasis produce thick and viscous mucus that leads to mucus 
stasis, airway obstruction, persistent infection, inflammation, and a progressive decline in 
lung function. These features are the hallmarks of CF lung disease and result in limited life 
expectancy (1–3).
In 1989, the identification of the CFTR gene on chromosome 7 and its most common 
mutation, ΔF508 CFTR, raised hope for a cure that would address the underlying cause of 
CF (4–6). Intense high-throughput screening approaches over the last decade have yielded 
compounds that modulate mutant CFTR function (7–16). Small-molecule compounds that 
rescue mutant CFTR can be assigned to 2 groups: 1) “corrector” compounds that promote 
maturation and delivery of CFTR proteins to the apical surface and 2) “potentiator” 
compounds that activate apical CFTR by increasing the open time of the channel.
The FDA recently approved the CFTR potentiator compound VX-770 (ivacaftor; trade name 
Kalydeco) as the first drug that directly restores CFTR activity in CF patients who carry a 
G551D mutation (17–20). G551D CFTR reaches the plasma membrane of epithelial cells, 
but the protein exhibits a gating defect that abolishes ATP-dependent channel opening and 
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causes severe CF. In patients carrying a G551D mutation, VX-770 has proven to be 
effective in clinical trials (18, 19), in which treated patients exhibited marked improvements 
in sweat chloride values and pulmonary function. The development of a CFTR-targeted drug 
that benefits CF patients marked a breakthrough in the treatment of CF. Unfortunately, 
because less than 5% of the CF population have the G551D mutation, this specific therapy 
helps only a limited number of patients (21, 22). 90% of CF patients carry the ΔF508 
mutation, which produces a protein that does not mature normally and does not traffic to the 
plasma membrane. VX-770 treatment did not benefit CF subjects with the ΔF508 mutation 
(23), likely because this compound only acts on protein that has trafficked to the plasma 
membrane. Based on these findings, an attractive therapeutic strategy for the ΔF508 CF 
patient population is to promote transfer of the ER-retained ΔF508 CFTR protein to the 
plasma membrane using small-molecule corrector compounds (24–26). Studies have 
estimated that the extent of correction in ΔF508 airway epithelial cells must approximate 
10–25% of wild-type (WT) CFTR function to provide therapeutic benefit (27, 28). In vitro 
treatment of CF airway epithelial cultures homozygous for the ΔF508 mutation with the 
most promising corrector compound, VX-809 (lumacaftor), resulted in CFTR function of 
~14% relative to non-CF (“wild-type”) human airway epithelial cells (8). However, 
administration of VX-809 did not provide a significant therapeutic benefit for ΔF508 CF 
patients in recent clinical trials, most likely because ΔF508 CFTR correction in vivo was less 
than 10% of wild-type levels, the lower limit of detection, and thus no mature ΔF508 CFTR 
protein was observed (29). Therefore, a logical next step was to combine corrector and 
potentiator therapies to rescue ΔF508 and increase protein function (24, 30, 31). One of the 
most promising current clinical trials designed to optimize ΔF508 CFTR function involved 
the administration of the corrector VX-809 with the potentiator VX-770. Increases in 
VX-809-rescued ΔF508 CFTR function have been demonstrated after acute administration 
of VX-770 in primary human airway epithelial cells from CF patients (8) and human 
organoids derived from CF (ΔF508/ΔF508) intestinal tissue (32). Surprisingly, chronic co-
administration of VX-809 and VX-770 in Phase 2 and 3 studies produced only small 
improvements in lung function in CF patients homozygous for the ΔF508 CFTR mutation 
(31, 33).
The aim of this study was to elucidate the molecular mechanism(s) underlying the limited 
improvement in ΔF508 CFTR function when a corrector, VX-809 and a potentiator, VX-770 
were co-administered to CF patients. We therefore investigated whether there were 
unexpected effects of chronically exposing CF cultures in vitro to VX-809 and VX-770, as 
would be achieved by oral dosing in clinical trials. A combination of CFTR bioelectric and 
biochemical approaches were utilized to investigate this interaction. Human bronchial 
epithelial (HBE) cells were used for these studies and exposed for 48 hrs to clinically 
relevant concentrations of both compounds. In addition, because of the success of VX-770 
in CF patients with the G551D mutation, it has recently been suggested that treatment with 
VX-770 may be a pharmacological approach to enhance CFTR function in patients with 
chronic obstructive pulmonary disease (COPD) (34). Accordingly, similar experimental 
approaches were utilized to explore the effects of VX-770 on WT CFTR, which matures 
normally and traffics to the plasma membrane.
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Acute and chronic VX-770 treatments rescue G551D CFTR function
It has been recently demonstrated that acute VX-770 administration increased CFTR 
function in cell lines expressing G551D CFTR and augmented Cl− secretion in primary 
human bronchial epithelial (HBE) cells derived from CF patients with the G551D mutation 
on one allele and the ΔF508 mutation on the other allele (7). To compare the effects of 
chronic versus acute VX-770 drug administration in CF airway epithelia with a G551D 
mutation, we used well-differentiated primary CF HBE cultures (G551D/ΔF508) as a model. 
Cultures were treated chronically for 48 hrs with VX-770 or vehicle in the basolateral 
medium, and then transepithelial short-circuit currents (ISC) were measured in Ussing 
chambers (Fig. 1). Cultures were exposed to amiloride to inhibit the epithelial Na+ channel 
(ENaC) and subsequently forskolin to stimulate Cl− secretion by CFTR. As previously 
reported, acute administration of VX-770 (aVX770) raised Cl− secretion after forskolin 
administration (Fig. 1A). Chronic VX-770 (cVX770) administration raised forskolin 
responsiveness but eliminated subsequent responses to acute VX-770 administration (Fig. 
1A,B,C, Table S1). Cultures chronically treated with VX-770 exhibited total CFTR-
mediated responses (Fig. 1D) and inhibition with CFTRinh-172 (Fig. 1E) equal to cultures 
treated with forskolin and acute VX-770.
Chronically VX-770-treated G551D/ΔF508 HBE cultures also exhibited a decrease in 
amiloride-sensitive currents (Fig. S1A, Table S2), suggesting decreased ENaC function. 
This finding is consistent with restoration of CFTR-mediated ENaC inhibitory activity (35, 
36) because cleavage of ENaC was diminished in chronically VX-770-treated CF cultures 
(Fig. S1B). The average UTP responsiveness, an index of Ca2+ activated Cl− channel 
(CaCC) activity, was reduced with chronic as compared to acute VX-770 administration 
(Fig. S1C, Table S2).
In sum, these results demonstrate that both acute and chronic treatment with VX-770 
improved CFTR function in HBE cells with the G551D mutation, consistent with clinical 
studies.
Chronic VX-770 treatment inhibits functional rescue of ΔF508 CFTR
CF patients harboring the ΔF508 CFTR mutation, which produces protein maturation and 
trafficking defects, have little/no CFTR at the cell surface. Consequently, treatment with a 
corrector compound, such as VX-809, is required for VX-770 to potentiate surface-localized 
ΔF508 CFTR. To mimic clinical administration of VX-809 and VX-770 as a combination 
therapy for the ΔF508 CF patients, primary CF HBE cultures (ΔF508/ΔF508) were treated 
with both pharmacological agents for 48 hrs and then Ussing chamber experiments were 
performed to measure ΔF508 CFTR function (Fig. 2, Table S3).
Anion efflux across the apical epithelial membrane of airway epithelia in response to cAMP 
is mediated by CFTR and was not substantial in vehicle-treated ΔF508/ΔF508 CF HBE 
cultures Fig. 2A,B; Vehicle). However, VX-809 administration produced ΔF508 CFTR 
correction as evidenced by stimulation of Cl− secretion (Fig. 2). Specifically, correction by 
VX-809 produced responses to forskolin (Fig. 2A, B; VX809) that were enhanced by acute 
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administration of VX-770 (Fig. 2A,C). These data indicate that acutely applied VX-770 
further activated (“potentiated”) VX-809-rescued ΔF508 CFTR. However, the CFTR-
mediated ISC increase after addition of VX-770 to corrector-rescued ΔF508 CFTR was 
transient. The ISC decrease over time may be indicative of a rapidly decreasing quantity of 
functional protein at the apical membrane.
In contrast, rescue of ΔF508 CFTR function was dramatically decreased in cultures that had 
been chronically treated with VX-809 and VX-770 compared to VX-809 alone (Fig. 2A: 
VX809 vs. VX809+VX770). This loss of “corrected” function was reflected in reduced Cl− 
secretion responses to forskolin (Fig. 2B) and reduced inhibition of stimulated CFTR Cl− 
secretion with CFTRinh-172 (Fig. 2D). Thus, these data contrast with the significant (P = 
0.0177) acute VX-770 responses in VX-809-treated cultures (Fig. 2C). Again, we noticed 
that the response to UTP-stimulated ISC decreased upon chronic VX-770 treatment (Figs. 
2A and S1D).
We also tested the impact of chronic VX-770 treatment on ΔF508 correction in CF HBE 
cultures (ΔF508/ΔF508) by corrector compound VX-661. Similar to VX-809-treated CF 
cells, VX-661-corrected CF HBE cells showed a drastic reduction in forskolin-mediated 
CFTR function when VX-770 was chronically added (Fig. S2, Table S4).
Chronic VX-770 administration hinders correction by decreasing the stability of corrected 
ΔF508 CFTR
To explore the mechanism(s) mediating the VX-770-induced reduction of VX-809-corrected 
ΔF508 CFTR function, we used Western blotting techniques to analyze protein maturation 
and turnover. In normal HBE cells, we detected a mature, complex glycosylated form, band 
C (Fig. 3A, NL: *), with a substantially greater molecular weight than the immature band B 
(Fig. 3A, NL: ●). In contrast, only band B could be detected in vehicle-treated ΔF508/
ΔF508 CF HBE cells (Fig. 3A, CF). As previously reported, treatment with VX-809 alone 
resulted in formation of a modest amount of mature band C in CF HBE cultures, which was 
not present in vehicle- or VX-770-treated CF cells (Fig. 3A, CF). However, when CF cells 
were treated chronically with both VX-809 and VX-770, the amount of mature ΔF508 
CFTR was diminished, and instead the ΔF508 CFTR protein appeared almost exclusively as 
immature band B. These data suggest that chronic VX-770 treatment impeded correction of 
ΔF508 CFTR by VX-809. We investigated the impact of chronic VX-770 treatment on 
protein stability by measuring the turnover rate of corrected ΔF508 CFTR. ΔF508 CFTR 
was stably expressed in baby hamster kidney (BHK-21) cells and corrected with VX-809 in 
the presence and absence of VX-770. Rescue with VX-809 was performed at 27°C for 24 
hrs because VX-770 prevented VX-809 mediated correction of ΔF508 CFTR at 37°C (Fig. 
3A). After rescue, cells were shifted to 37°C and protein biosynthesis was inhibited by 
addition of cycloheximide. The amount of remaining mature ΔF508 CFTR was then 
measured after 3 and 6 hrs. The turnover rate of rescued ΔF508 CFTR band C increased and 
the half-life accordingly decreased by ~2.5 fold in the presence of VX-770 (Fig. 3B,C, Table 
S5), whereas the decrease in band B levels was not affected by the presence of VX-770 (Fig. 
3B). These data clearly show that VX-770 decreased the stability, and thus increased the 
turnover rate, of VX-809-rescued ΔF508 CFTR.
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VX-770 affects correction of ΔF508 CFTR in a dose-dependent relationship
Lower concentrations of VX-770 were chronically administered to ΔF508/ΔF508 CF HBE 
cells to study the dose effect on VX-809-rescued ΔF508 CFTR (Fig. 4). To obtain an 
average measure of CFTR-mediated ISC for the period spanning forskolin stimulation to 
CFTR inhibition, the area under the curve (AUC) was calculated for this interval. Dividing 
AUC by time yielded average CFTR ΔISC between activation and inhibition. When 1 µM 
VX-770 was administered chronically with VX-809, the forskolin responses of CF HBE 
cells were intermediate between cells treated with VX-809 alone and cells treated with 5 µM 
VX-770 and VX-809 (Fig. 4A,B, Table S6). There was a significant reduction in AUC in 
corrector-treated cells with 1 µM versus 5 µM VX-770 (P =0.0049). Although there was not 
a significant difference in AUC of VX-809-treated cells with 50 nM VX-770 versus VX-809 
alone (Fig. 4B), this low dose of VX-770 caused a rapid decline of the slope after forskolin 
treatment (Fig 4C, Table S7). Chronic treatment with either 50 nM or 1 µM VX-770 
eliminated responses to acute VX-770 (Fig. 4A,C). Western blots to detect mature band C 
protein in CF HBE cells confirmed that VX-809 rescue was inhibited by VX-770 in a dose-
dependent manner. As the concentration of VX-770 increased, the amount of VX-809-
corrected ΔF508 CFTR decreased (Fig. 4D, E, Table S8).
Chronic VX-770 treatment decreases function of normal (wild-type) CFTR
To investigate the effects of chronic VX-770 treatment on normal (NL) CFTR, we measured 
anion secretion of NL primary HBE cultures treated with VX-770 for 48 hrs (Fig. 5). 
Strikingly, administration of 5 µM VX-770 reduced CFTR-mediated Cl− secretion, as 
reflected by decreased forskolin responses (Fig. 5A,B,C, Table S9) and decreased inhibition 
of CFTR-mediated current by CFTRinh-172 (Fig. 5A,D). These functional responses were 
paralleled by a decrease in CFTR band C (Fig. 5E). In cells chronically treated with 
VX-770, we also observed a consistent reduction in amiloride-sensitive current (Fig. S3A, 
Table S2) and a substantial inhibition of UTP-sensitive current (Fig. S3B, Table S2) similar 
to that observed in CF HBE cells (Fig. S1A,C,D, Table S2).
Chronic treatment with VX-770 does not alter HBE cell integrity or barrier functions
As a test for the specificity of chronic VX-770 effects, we analyzed whether fundamental 
epithelial parameters were altered in HBE cultures chronically treated with VX-770 (Fig. 6). 
The morphology of highly differentiated ciliated HBE cultures was identical in cells treated 
with vehicle (DMSO) or VX-770 (Fig. 6A). Transepithelial resistance (Rt) of primary HBE 
cultures was also not affected by chronic VX-770 exposure (Fig. 6B, Table S10). The 
inhibition by VX-770 of both Na+ absorption (amiloride-sensitive ISC) and Cl− secretion and 
currents (CFTR- and CaCC-mediated ISC) raised the possibility that driving forces for ion 
transport, in part generated by Na+/K+ ATPase activity, were perturbed by VX-770. 
Nystatin, a polyene antibiotic that enables monovalent cations to permeate biological 
membranes and raise Na+/K+ ATPase activity, did not produce significantly different ISC 
responses when applied to vehicle- or VX-770-treated HBE cultures (Fig. 6C, Table S10), 
suggesting intact Na+/K+ ATPase activity (37). Measurements of intracellular 
concentrations of VX-809 and VX-770 by mass spectrometry confirmed the presence of 
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these compounds in treated HBE cultures and indicated that cellular VX-809 concentrations 
were not affected by the presence of VX-770 (Fig. S4, Table S11).
Destabilization by VX-770 is beneficial for G551D, but not for wild-type, or ΔF508 CFTR 
function
A high C:B band ratio indicates normal CFTR protein maturation. Biochemical analysis by 
Western blotting showed that chronic VX-770 treatment dramatically reduced the amount of 
mature CFTR in both NL cultures expressing wild-type CFTR (Figs. 5E and 7A) and 
VX-809-rescued ΔF508 CFTR in CF HBE cells (Figs. 3A and 4E). Indeed, the C:B band 
ratio decreased with chronic VX-770 exposure by more than 50% in NL cultures (Fig. 7B, 
NL, Table S12). In contrast, the levels of mature (band C) G551D CFTR detected in 
G551D/ΔF508 CF HBE cultures were not significantly diminished by chronic exposure to 5 
µM VX-770, suggesting that G551D was resistant to the destabilizing effects of VX-770 
(Fig 7A, G551D/ΔF508).
To explore the relationship between VX-770, VX-809, and CFTR protein stability, we 
performed calculations of thermodynamic stability of CFTR protein utilizing a structural 
homology model (38). This model revealed that CFTR amino acid F508 is located at the 
nucleotide binding domain 1- cytoplasmic loop 4 (NBD1-CL4) interface (Fig. 7C), and 
therefore participates in important interdomain interactions. Thus, in ΔF508 CFTR, the 
deletion of amino acid F508 not only reduces the stability of the NBD1 domain, but 
importantly, may destabilize multidomain assembly of CFTR (39–41). In contrast, in this 
structural model of CFTR, amino acid G551 is positioned between the 2 NBDs (Figs. 7C, 
S5), and the G551D mutation is thought to contort NBD dimer formation and abolish ATP-
dependent channel opening by disrupting the signature sequence in NBD1 (42). To evaluate 
whether the G551D mutation also affects the overall stability of CFTR by inducing 
conformational restructuring of the protein, we computationally estimated the ΔΔG for 
G551D CFTR (43, 44). We found that G551D had a stabilizing effect on the CFTR protein 
(ΔΔG = -8.1 kcal/mol).
Discussion
Potentiator compounds act on mutant CFTR channels that are on the surface of epithelial 
cells. VX-770 has been approved as a pharmacological agent to treat CF patients with at 
least one copy of the G551D mutation. However, the most common mutant protein in CF 
patients, ΔF508 CFTR, is not found at the cell surface. ΔF508 CFTR has a folding defect 
and is retained in the ER but can be partially rescued by corrector compounds that promote 
delivery of a small proportion of mutant ΔF508 proteins to the cell surface. Corrector-
rescued ΔF508 CFTR is reported to have a shorter half-life at the cell surface (45–49) and 
exhibits increased thermal inactivation as well as a gating defect when compared to WT 
CFTR (47, 50–55).
The efficacy of orally administered VX-770 was established in clinical trials in G551D CF 
patients by multiple outcome measurements (30, 56–58). The clinical benefit of potentiation 
of G551D function was predicted from the effectiveness of acute administration of VX-770 
in Ussing chambers, which measured rates of Cl− secretion across primary G551D/ΔF508 
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CFTR airway epithelial cultures (7). Our studies confirmed that acute VX-770 
administration restored CFTR Cl− secretion activity in HBE cells from patients carrying the 
G551D mutation. Further, our data demonstrated that G551D/ΔF508 cultures chronically 
treated with VX-770 also exhibited increased Cl− secretion via G551D CFTR, but 
stimulation with forskolin, which raises intracellular cAMP, was required to activate Cl− 
secretion. This result could suggest a benefit from administering cAMP-raising β2-
adrenergic receptor agonists as a routine part of the treatment for G551D CF patients 
receiving VX-770. Overall, improvement in G551D CFTR activity with acute VX-770 in 
vitro was also observed with chronic in vitro VX-770 administration.
VX-809 appears to restore approximately 15% of normal function in ΔF508/ΔF508 CF HBE 
cells (8). However, 10–25% of CFTR function is estimated to be required to overcome CF 
symptoms (28). Therefore, a combination of VX-809 with a potentiator compound to further 
enhance ΔF508 function may be necessary. Although acute treatment with VX-770 has been 
reported to enhance VX-809-rescued ΔF508 activity (8), our data revealed that chronic 
application of VX-770 in combination with VX-809 or VX-661 did not. Chronic co-
administration of VX-770 with either corrector to ΔF508/ΔF508 CF HBE cultures produced 
Cl− secretory responses that were smaller than responses to corrector alone. Our data 
suggest that the reduced capacity for Cl− secretion after chronic VX-770/VX-809 exposure 
reflected an increased turnover rate of corrected ΔF508 CFTR. The VX-770-induced 
reduction of ΔF508 correction observed in primary CF HBE cells was dose-dependent as 
measured by functional and biochemical approaches. We did not detect alterations in 
physiological properties of HBE cells that would suggest that toxic effects contributed to 
CFTR dysfunction after chronic VX-770/VX-809 treatment. Thus, our studies suggest that 
data describing the effectiveness of acute addition of VX-770 to VX-809-treated ΔF508 CF 
HBE cells do not predict the outcome for chronic VX-770/VX-809 administration.
ΔF508 CFTR has been shown to exhibit an increased thermodynamic instability of NBD1 
(51, 52, 59) and improper assembly of NBD1 into a complex with intracellular loop 4 
(ICL4) of the second membrane-spanning domain (MSD2) (38). The recently published data 
on CFTR domain fragments strongly suggest that VX-809 targets MSD1 of CFTR to 
suppress folding defects of ΔF508 CFTR by enhancing interactions among NBD1, MSD1 
and MSD2 (60, 61). Thus, VX-809 is predicted to enhance function of ΔF508 by increasing 
its stability (Fig. 7D). Importantly, chronic exposure to VX-770 appeared to reverse the 
stabilization effect of VX-809 in ΔF508 CFTR. Chronic VX-770 treatment resulted in a 
severe reduction in rescued ΔF508 CFTR protein due to destabilization of rescued protein as 
reflected by a 2.5× increase in turnover rate. In contrast, G551D CFTR was more resistant to 
destabilization and loss of mature CFTR protein with chronic VX-770 exposure than WT or 
ΔF508 CFTR.
Our CFTR computational structural model (38) allows us to speculate how VX-770 may 
interact with WT or mutant CFTR proteins to alter protein stability. CFTR requires 
conformational flexibility to function properly (39, 50). The flexibility and stability of the 
CFTR protein is finely tuned and precisely balanced, which is a requirement for its ability to 
function properly as a regulated ion channel. The inherent increase in stability of the G551D 
protein may render it too rigid and inflexible (stable) for proper channel opening under basal 
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cAMP-stimulated conditions. However, a decrease in stability mediated by VX-770 may 
render the G551D molecule more flexible and allow it to function as a cAMP-regulated Cl− 
channel (Fig. 7D). In contrast, destabilization of WT (ideal stability) or VX-809-rescued 
ΔF508 CFTR (low stability) by VX-770 bound to the CFTR molecule resulted in decreased 
WT CFTR function and absent ΔF508 CFTR function. These considerations reveal that 
chemical correction of low stability CFTR mutants is complicated and necessitates 
precision.
Some airway diseases such as chronic obstructive pulmonary disease (COPD) have been 
associated with lessened CFTR function and consequently VX-770 has been suggested as a 
potential therapy (34). In a study that modeled the effects of VX-770 on COPD patients, 
reduction of CFTR function was achieved by exposing primary HBE cultures to cigarette 
smoke extract, and these cultures were subsequently exposed to acute administration of 
VX-770, which led to augmented CFTR-mediated currents (34). The finding that acute 
VX-770 treatment enhanced WT CFTR function contrasts with our finding that chronic 
treatment with VX-770 reduced WT CFTR function. In addition, forskolin-stimulated ISC in 
NL HBE cultures chronically treated with VX-770 was not stable over time, as indicated by 
the downward sloping trace. These functional data, coupled with our observations that the 
amount of mature WT CFTR was reduced by the continuous presence of VX-770, do not 
favor VX-770 as a therapy to enhance CFTR function in COPD.
Although potentiation of more rare CFTR mutants with partial defects in CFTR processing 
was recently detected upon acute VX-770 treatment in Fisher rat thyroid (FRT) cells 
overexpressing these variants (62), our data raise the concern that potentiation with chronic 
VX-770 treatment may not be observed in airway epithelia expressing these rare mutations. 
To optimize combination therapy for both ΔF508 and rare CFTR processing mutations, 
minimizing interference of potentiator with corrector activity is required. One approach may 
be to finely tune the dosing regimens for potentiator compounds. Studies by Van Goor et al. 
(7) indicate that the EC50 for acute application of VX-770 differs remarkably in G551D/
ΔF508 (EC50: 236 ± 200 nM) and ΔF508/ΔF508 (EC50: 22 ± 10 nM) HBE cultures. These 
data together with our findings, which demonstrate that inhibition of correction by VX-770 
is dose dependent, suggest that drug concentrations are very critical and attempts to optimize 
potentiator activity on channel function while minimally affecting turnover rate of mutant 
CFTR should be considered. As a second approach, improved potentiator compounds that 
do not interfere with ΔF508 CFTR correction and turnover are needed.
After chronic VX-770 treatment, we also observed diminished Cl− secretory responses to 
additions of the P2Y2 receptor agonist, UTP. UTP-stimulated Cl− secretion is elevated in CF 
airway epithelia and may compensate for the lack of CFTR function in vivo (63–65). 
Reduction of UTP-stimulated CaCC activity may constitute a disadvantage in CF airways, 
particularly if insufficient amounts of CFTR have been rescued. Thus, monitoring CaCC 
activity may be useful in future clinical corrector/potentiator studies.
We observed a decrease in amiloride responses in the presence of chronic VX-770. While 
the effects in CF cells can be explained by the restoration of CFTR inhibiting activity (36), 
the inhibition of ENaC-mediated Na+ absorption in NL HBE cells raises the possibility that 
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VX-770 may have off-target effects. Thus, it may be useful to measure ENaC function in 
future VX-770 clinical trials. Although a decline in ENaC function may be beneficial for CF 
patients, diminution of Cl− channels other than CFTR may be a disadvantage for 
maintaining adequate hydration of CF airways. The recent observation that VX-770 has 
antimicrobial properties in vitro suggests that it may also display off-target effects in vivo 
(66).
A limitation of our studies is that our experiments were performed in primary HBE cultures 
and not in vivo. However, primary HBE cultures are a well-established, near-physiologic 
system that is the most relevant model for studying CFTR function in airway epithelia, the 
tissue most affected by CF. Drug concentrations, turnover, and formation of metabolites 
may also differ in vitro and in vivo, which are crucial parameters to consider when 
extrapolating our data to the clinic. We therefore selected in vitro doses that mimicked 
clinically measured drug concentrations. For example, 5-day VX-770 treatments with 150 
mg or 450 mg (administered as one dose/day) in patients resulted in VX-770 concentrations 
in blood plasma of 1.4 µg/ml and 5.5 µg/ml, respectively (67), which are equivalent to ~3.5 
µM and ~14 µM. Current clinical trials test VX-770 doses in this range (250 mg taken twice 
per day). Thus, the concentrations tested in our studies in vitro appear relevant to the clinical 
experience.
We measured intracellular concentrations of VX-809 and VX-770, which revealed that these 
compounds (particularly VX-770) accumulated in cells and reached much higher 
concentrations than in the surrounding media. To determine whether the presence of 
VX-770 might have a negative impact on the intracellular concentration of VX-809, we 
obtained measurements of VX-809 concentrations in cell lysates with increasing 
concentrations of VX-770 and observed that the intracellular concentration of VX-809 was 
not affected by the presence of VX-770. Thus, comparisons of drug concentrations from in 
vitro and in vivo tissues may be useful in the future.
Because there are no corrector compounds available that provide sufficient rescue of ΔF508 
in CF airways in vivo to alleviate symptoms of CF, potentiation of the small amount of 
corrected ΔF508 CFTR is required. However, combination approaches to restore ΔF508 
CFTR function in CF to date have not considered drug-drug interactions of clinically 
relevant co-administered modulator compounds. Based on our study and the confirmatory 
data of Veit et al. (68), knowledge of the interactions and interference between corrector and 
potentiator compounds is essential for successful therapy of the most prevalent mutation in 
CF patients, most of whom carry at least one allele of the ΔF508 mutation. Furthermore, 
understanding the impact that potentiator compounds, such as VX-770, have on the stability 
of apical WT CFTR may also be important for other airway diseases that would benefit from 
augmentation of CFTR function.
Materials and Methods
Study design
Simultaneous treatment with small-molecular compounds, VX-809 or VX-661, together 
with VX-770 (Selleck Chemicals), is currently being examined as therapy for CF patients 
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with the mutation, ΔF508. Although in vitro studies examining acute treatment with this 
drug combination have been conducted, we sought to determine the impact of chronic 
treatment (48 hrs) with these compounds in primary human bronchial epithelial (HBE) cells. 
Primary HBE cells from normal (NL) or CF patients were obtained from bronchi of human 
lung tissue, as previously described (69, 70). To evaluate CFTR function HBE cultures 
chronically treated with compounds were mounted in Ussing chambers to measure short-
circuit currents (ISC) (65, 71, 72). We examined differentiated primary CF HBE cells from 
at least 3 individuals for each genotype. To visualize the amount of mature and immature 
CFTR protein from HBE cultures, CFTR from whole-cell lysates was immunoprecipitated 
as previously described (35, 73) and Western blots were performed. Previously created baby 
hamster kidney (BHK-21) stably expressing ΔF508 CFTR (48), were used in cycloheximide 
chase studies to examine the rate of protein turnover.
Cell culture
Primary HBE cells were obtained from bronchi of human lung tissue (69, 70) under a 
protocol approved by the University of North Carolina Medical School Institutional Review 
Board. Primary NL and CF HBE cells were seeded at passage 2 on collagen-coated Millicell 
CM inserts (Millipore) and maintained at an air-liquid interface (ALI) at 37°C in 5% CO2 
for 3–4 weeks, which allowed the cells to become fully differentiated.
BHK-21 cells were obtained from the American Type Culture Collection and grown at 37°C 
in 5% CO2. BHK-21 cells stably expressing Extope-ΔF508 CFTR were created previously 
and maintained as described (48).
Immunoprecipitation and Western blotting
Whole-cell lysates were prepared as described previously (74). CFTR was 
immunoprecipitated as described previously (35, 73) and isolated using Protein A/G PLUS 
agarose (Santa Cruz Biotechnology). Samples were separated on 4–20% gradient SDS-
PAGE gels (Bio-Rad) and then transferred to nitrocellulose. Blots were probed with mouse 
monoclonal anti-CFTR antibodies and then with IR Dye 680-goat anti-mouse IgG 
(Molecular Probes). Anti-actin (Cell Signaling) or anti-tubulin (LI-COR) was used as a 
loading control. Protein bands were visualized using an Odyssey Infrared Imaging System 
(LI-COR).
Cycloheximide chase to study turnover of rescued ΔF508 CFTR
BHK-21 cells expressing Extope-ΔF508 CFTR were pretreated with compounds (VX-809, 5 
µM; VX-770, 5 µM) for 24 hrs at 27°C before treatment with cycloheximide (200 µg/ml; 
Sigma) in the presence of compounds during chase times at 37°C. Whole-cell lysates were 
prepared and subjected to Western blotting.
Histology and microscopy
Primary HBE cultures grown at ALI on Millicell inserts were washed in PBS and fixed in 
10% neutral buffered formalin prior to being embedded in paraffin and hematoxylin-eosin 
stained at the UNC CF Histology Core. Slides were viewed on a Leica DMIRB Inverted 
Microscope with a 40× 1.0 numerical aperture oil objective.
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ISC Measurements in Ussing chambers
In Ussing chambers (Physiological Instruments) HBE cultures were equilibrated to 37°C in 
a bilateral bath of Krebs-bicarbonate-Ringer buffer (KBR; in mM: 140 Na+, 120 Cl−, 5.2 
K+, 1.2 Ca2+, 1.2 Mg2+, 2.4 HPO42−, 0.4 H2PO4−, 25 HCO3−, and 5 glucose, pH 7.4) and 
circulated with 95% O2-5% CO2. Short-circuit currents (ISC) were measured as previously 
described (65, 71, 72). All NL HBE cultures were measured in bilateral KBR. Unless noted 
otherwise, CF HBE cultures were measured with high potassium, low chloride (HKLC) 
buffer applied apically and KBR applied basolaterally, creating a Cl− gradient (5 mM/120 
mM). Amiloride (100 µM) was added to block ENaC, followed by forskolin (10 µM), 
VX-770 (5 µM) and, if applicable, genistein (10 µM) to stimulate CFTR. CFTR was then 
inhibited with CFTRinh-172 (10 µM) and response to UTP (100 µM) was examined. In some 
experiments, nystatin (40 µM, apical) was added at the end of the measurements. Data were 
analyzed using Acquire and Analysis (version 2.3) software (Physiologic Instruments). ISC 
traces were imported to and processed in Origin 9.0.0. (OriginLab Corporation).
Detection of VX-770 and VX-809
Mass spectrometric (MS) methods were developed to detect VX-770 and VX-809 using 
strategies similar to those previously described (75, 76). VX-770 was detected by 
monitoring transition of parent to daughter ion of m/z 393.3→171.1 in positive mode MS, 
with VX-809 detected by monitoring the transition m/z 453.3→197.1. Each compound 
generated a single peak using previously described liquid-chromatography-tandem MS (LC-
MS/MS) methods (75, 76), with run times of 11.1 and 10.8 minutes, respectively. To 
quantify drug concentrations in epithelial cells, cell lysates were extracted × 2 with equal 
volume of MTBE (Sigma), which was then lyophilized to dryness under vacuum 
centrifugation. Lyophilized samples were resuspended in a volume of 20% methanol in 
water equal to the original lysate volume, extracted, and 5 µl analyzed by LC-MS/MS as 
above. To control for matrix effects and variable recovery during extraction, untreated 
lysates were spiked with known concentrations of VX-770 and VX-809 and extracted in 
parallel. Concentrations in cell lysates were assessed by examining signal relative to the 
spiked samples.
Computational stability calculation
We computationally estimated the ΔΔG of mutation for G551D mutant CFTR using the Eris 
suite as described previously (43, 44). Eris algorithms re-pack the side chains and evaluate 
the new free energy according to a physical force field upon the substitution of the relevant 
residue.
Statistical analysis
Results are presented as means of average response per primary HBE cell donor and error 
bars are the standard error of the mean (SEM). Statistical analysis was performed by an 
unpaired two-tailed Student’s t test in GraphPad Prism version 6.02 (GraphPad Software). P 
values of < 0.05 were considered to indicate statistical significance.
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Figure 1. VX-770 treatment restores G551D function
Electrophysiological properties of G551D/ΔF508 cultures analyzed in Ussing chambers 
treated chronically with VX-770 (cVX770, 5 µM for 48 hrs) or with vehicle (0.1% DMSO). 
(A) Representative recording of ISC measured in Ussing chambers. Quantification of 
response to treatment with (B) forskolin (significant difference between vehicle and 
cVX770, *P = 0.0009), (C) acute VX-770 (aVX770) (significant difference between vehicle 
and cVX770, *P = 0.0054), (D) forskolin + aVX770, (E) CFTRinh-172. Primary CF HBE 
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cultures (G551D/ΔF508) were derived from 3 different patients, 3–4 replicates were 
performed per patient for a total of 10 measurements per treatment.
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Figure 2. Chronic VX-770 treatment inhibits functional rescue of ΔF508
(A) Representative ISC traces of CF HBE cells recorded in Ussing chambers. Primary CF 
HBE cells (ΔF508/ΔF508) were treated with vehicle (DMSO) or VX-809 +/−VX-770 for 48 
hrs at 5 µM each. (B) ΔISC response to forskolin observed in VX-809-treated CF HBE cells 
(*P = 0.0033, VX809 vs. vehicle) was prevented by chronic VX-770 treatment and 
significantly different from VX-809-treated cells (#P = 0.0147, VX809 vs. 
VX809+VX770). (C) CF HBE cells treated with VX-809 responded to acute VX-770 
exposure (*P = 0.0177, VX809 vs. vehicle). This response was significantly abrogated in 
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VX-809 + VX-770-treated cells (#P = 0.0031, VX809 vs. VX809+VX770). (D) The 
response to CFTRinh-172 observed in VX-809-treated cells (*P = 0.0209, VX809 vs. 
vehicle) was significantly decreased in VX809+VX770-treated cells (#P = 0.0006, VX809 
vs. VX809+VX770). Primary HBE cultures (ΔF508/ΔF508) were derived from 6 different 
patients, 2–4 replicates were performed per patient for a total of 15 measurements per 
condition.
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Figure 3. VX-770 diminishes biochemical correction by increasing turnover of corrected ΔF508 
CFTR
(A) CFTR Western blot of normal (NL) and CF HBE cultures treated with VX-809 (5 µM) 
+/−VX-770 (5 µM) for 48 hrs. * indicates the mature, complex glycosylated form of CFTR, 
band C; ● indicates the immature band B. (B) Turnover of rescued ΔF508 in BHK-21 cells. 
ΔF508 was rescued at 27°C in the presence of VX-809 +/− VX-770 for 24 hrs. After adding 
cycloheximide (200 µg/ml, 37°C) cells were lysed at the indicated times and analyzed by 
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Western blotting. (C) Quantification of remaining band C over time, normalized to actin (n 
= 3).
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Figure 4. VX-770-induced hindrance of ΔF508 correction is dose-dependent
(A) ISC traces of CF HBE cells (ΔF508/ΔF508) recorded in Ussing chambers. CF HBE cells 
were treated as indicated (VX-809: 5 µM, VX-770: 1 or 5 µM) for 48 hrs. (B) CFTR 
function in VX-809-treated cells decreased as chronic VX-770 concentrations increased. 
Significant reduction of the area under the curve (AUC)/min calculated from the time period 
between CFTR stimulation by forskolin and CFTR inhibition by CFTRinh-172 (yields 
average ΔIsc (µA/cm2)) was observed in CF cells chronically treated for 48 hrs with VX-809 
when compared to VX-809 and 1 µM VX-770, (*P = 0.0352). A further reduction was 
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detected when the chronic VX-770 concentration was increased to 5 µM (#P = 0.0049, 
VX-809 + 1 µM VX-770 vs. VX-809 + 5 µM VX-770). Primary CF HBE cultures were 
derived from at least 4 different CF patients; 2–5 replicates were performed per patient for a 
total of at least 14 measurements per condition. (C) In VX-809-corrected CF HBE cultures 
(ΔF508/ΔF508), the presence of chronic VX-770 at 50 nM caused a significant decline of 
the slope after forskolin treatment (*P = 0.0353, VX-809 vs. VX-809 + 50 nM VX-770). 
Primary CF HBE cultures were derived from 4 different patients; 3–5 replicates were 
performed per patient for a total of at least 15 measurements per condition. (D) 
Quantification of C:B band ratio in CF HBE cultures (ΔF508/ΔF508). CFTR C:B band ratio 
decreased in CF HBE cells as chronic VX-770 concentrations were increased. The C:B band 
ratio was significantly reduced in CF cells chronically treated for 48 hrs with VX-809 and 1 
µM VX-770 compared to VX-809 alone (*P = 0.0181), and a further reduction was detected 
when the chronic VX-770 concentration was increased from 1 µM to 5 µM (#P = 0.0151, 
VX-809 + 1 µM VX-770 vs. VX-809 + 5 µM VX-770). Primary CF HBE cultures (ΔF508/
ΔF508) from 4 different patients were analyzed. (E) Representative Western blot of CF 
HBE cells (ΔF508/ΔF508) showing decrease of VX-809-corrected ΔF508 as chronic 
VX-770 concentrations were increased.
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Figure 5. Chronic VX-770 treatment decreases function of wild-type CFTR
(A) Representative ISC traces of NL HBE cells recorded in Ussing chambers. Cultures were 
treated with vehicle (DMSO) or 5 µM VX-770 for 48 hrs. HBE cells that were chronically 
treated with VX-770 showed significantly reduced response to (B,C) forskolin (*P = 0.0198 
for forskolin peak and *P = 0.0008 for forskolin plateau) and (D) CFTRinh-172 (*P = 
0.0014). Primary HBE cultures were derived from 6 different individuals, 2–4 replicates 
were performed per individual for a total of 17 measurements per condition. (E) Western 
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blot of HBE cultures treated with VX-809 (5 µM) +/−VX-770 (5 µM) for 48 hrs. Mature 
CFTR was diminished in HBE cells that were chronically treated with VX770.
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Figure 6. Key physiological properties were not altered in chronically VX-770-treated HBE 
cultures
(A) Microscopy after hematoxylin and eosin (H&E) staining of HBE cultures did not reveal 
a detectable difference between VX-770- or vehicle-treated cells (bar = 10 m). (B) 
Transepithelial resistance (Rt) of primary HBE cultures was not altered after chronic 
treatment with VX-770. (C) Nystatin responses were not significantly different in primary 
HBE cultures that were treated with vehicle or VX-770 (48 hrs, 5 µM). Nystatin was added 
to the apical side in Ussing chambers. Primary HBE cultures were derived from 5 different 
individuals, and 2–4 replicates per individual were performed.
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Figure 7. VX-770 reduces stability of CFTR
(A) The amount of mature CFTR was reduced when NL HBE cells were chronically treated 
with VX-770 (48 hrs, 5 µM). G551D is more stable than NL CFTR and the amount of 
mature G551D protein in CF cultures (G551D/ΔF508) was not significantly reduced by 48 
hrs treatment with 5 µM VX-770. (B) Quantification of C:B band ratio with chronic 
treatment of VX-770 at 5 µM. C:B band ratio was significantly decreased in NL cells 
chronically treated for 48 hrs with 5 µM VX-770, (*P = 0.008) (n = 3, cultures from 3 
different NL individuals). The reduction of C:B band ratio in G551D/ΔF508 cells 
chronically treated for 48 hrs with 5 µM VX-770 was not statistically significant (n = 3, 
cultures from 3 different CF patients (G551D/ΔF508)). (C) Structural model showing 
positions of G551D and F508 in the CFTR molecule. (D) Illustration representing the 
proposed relationship between function and stability of CFTR variants. Wild-type CFTR has 
an intermediate stability that allows for optimal function. G551D CFTR is a more rigid 
protein that exhibits increased stability compared to wild-type CFTR but lacks sufficient 
function, presumably due to decreased flexibility. VX-770 decreases G551D CFTR stability 
and renders it a more flexible protein, resembling the stability and function of wild-type 
CFTR. However, VX-770 causes destabilization of wild-type CFTR and VX-809-corrected 
ΔF508 CFTR, diminishing their function. VX-809 increases the stability of ΔF508, bringing 
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it closer to resembling wild-type CFTR, but this increased stability is diminished when 
VX-770 is present.
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